home / stock / clnn / clnn news

CLNN News and Press, Clene Inc. From 03/13/23

Stock Information
Company Name: Clene Inc.
Stock Symbol: CLNN
Market: NASDAQ
Website: clene.com
Menu
CLNN CLNN Quote CLNN Short CLNN News CLNN Articles CLNN Message Board
Get CLNN Alerts

News, Short Squeeze, Breakout and More Instantly...
CLNN - The Charles Schwab, Banco Santander, First Republic among major financials premarket losers' pack

2023-03-13 08:57:19 ET First Republic FRC -64% amid woes regarding SVB, Signature collapse . Western Alliance WAL -54% amid woes regarding SVB, Signature collapse . PacWest PACW -40% amid woes regarding SVB, Signature collapse . Euda Health ( EUDA...
CLNN - Clene GAAP EPS of -$0.46 beats by $0.12, revenue of $0.47M beats by $0.13M

2023-03-13 07:20:39 ET Clene press release ( NASDAQ: CLNN ): FY GAAP EPS of -$0.46 beats by $0.12 . Revenue of $0.47M (-34.7% Y/Y) beats by $0.13M . Clene’s cash, cash equivalents and marketable securities totaled $23.3 million as of December 31, 2022, c...

CLNN - Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Amyotrophic lateral sclerosis (ALS): Significant survival benefits demonstrated across two ALS clinical trials, along with clinical improvements as early as six months CNM-Au8 ® associated with 74% lower risk of ALS clinical worsening events at six months supporting a sur...

CLNN - Clene adds 16% after new data for lead asset in ALS study

2023-03-09 07:15:02 ET Clene Inc. ( NASDAQ: CLNN ) shares gained ~16% pre-market Thursday in reaction to new results from its HEALEY ALS Platform Trial for lead candidate CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS), a rare neurological disease. Based o...
CLNN - CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

CNM-Au8 associated with a 74% lower risk (lower hazard ratio) of ALS clinical worsening, which included death, non-invasive ventilation >22 hours per day, tracheostomy, or feeding tube placement (p = 0.035) CNM-Au8 associated with a 98% lower risk of death or permanent assisted ven...

CLNN - Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

SALT LAKE CITY, March 08, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative dise...

CLNN - OPK, FRTX and QLGN among pre market gainers

2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
CLNN - Clene Nanomedicine to Participate in Roth's 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disea...

CLNN - Clene rises 7.5% on positive data from phase 2 trial of ALS treatment

2023-03-06 09:25:11 ET Clene ( NASDAQ: CLNN ) is trading 7.5% higher premarket after the company said new data from a phase 2 trial showed its therapy, CNM-Au8, preserved ALS patient function and slowed disease progression. Patients during the trial were given the...

CLNN - New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

Significant preservation of function (ALSFRS-R) from randomization to 48 weeks (p=0.0159) Significant preservation of function (ALSFRS-R) during the long-term open-label extension (OLE) week 24 to 120 weeks from randomization (p=0.0057) Significantly reduced risk of ALS ...
Previous 10 Next 10